Novartis is a Swiss drugmaker focused on innovative medicines after spinning off Sandoz, with heart, immunology, cancer and neuroscience franchises.
Sales of Entresto, which is losing patent protection, against newer drugs like Kisqali and Pluvicto, are the central question.